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ABSTRACT
OBJECTIVES: We investigated whether adrenal β−arrestin 1 (βarr1)-mediated aldosterone
production plays any role in post-MI HF progression.
BACKGROUND: Heart failure (HF) represents one of the most significant health problems
worldwide and new and innovative treatments are needed. Aldosterone contributes significantly
to HF progression after myocardial infarction (MI) by accelerating adverse cardiac remodeling
and ventricular dysfunction. It is produced by the adrenal cortex after angiotensin II (AngII)
activation of AngII type 1 receptors (AT1Rs), G protein-coupled receptors (GPCRs) that also
signal independently of G proteins. G protein-independent signaling is mediated by β−arrestin
(βarr) -1 and -2. We recently reported that adrenal βarr1 promotes AT1R-dependent aldosterone
production leading to elevated circulating aldosterone levels in vivo.
METHODS: Adrenal-targeted, adenoviral-mediated gene delivery in vivo in two-week post-MI
rats, a time point around which circulating aldosterone significantly increases to accelerate HF
progression, was performed to either increase the expression of adrenal βarr1 or inhibit its
function via expression of a βarr1 C-terminal-derived peptide fragment.
RESULTS: We found that adrenal βarr1 overexpression promotes aldosterone elevation postMI, resulting in accelerated cardiac adverse remodeling and deterioration of ventricular function.
Importantly, these detrimental effects of aldosterone are prevented when adrenal βarr1 is
inhibited in vivo, which markedly decreases circulating aldosterone post-MI. Finally, the
prototypic AT1R antagonist losartan appears unable to lower this adrenal βarr1-driven
aldosterone elevation.
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CONCLUSIONS: Adrenal βarr1 inhibition, either directly or with AT1R “biased” antagonists
that prevent receptor-βarr1 coupling, might be of therapeutic value for curbing HF-exacerbating
hyperaldosteronism.
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INTRODUCTION
Despite recent advances in prevention and management of heart disease, death due to
chronic heart failure (HF) continues to rise and new treatments are needed (1,2). Aldosterone is
one of a number of hormones with detrimental effects to the myocardium, whose circulating
levels are elevated in chronic HF (3). It can contribute significantly to HF progression after
myocardial infarction (MI) and to the morbidity and mortality of the disease (3-5). Its main
actions on the post-MI heart include (but are not limited to) cardiac hypertrophy, fibrosis, and
increased inflammation and oxidative stress, all of which result in adverse cardiac remodeling
and progressive loss of cardiac function and performance (5,6). Accordingly, plasma aldosterone
levels are a marker of HF severity (7,8) and aldosterone antagonists, such as spironolactone and
eplerenone, have well-documented beneficial effects in HF constituting a significant segment of
the chronic HF pharmacotherapeutic regimen (9,10).
Aldosterone is a mineralocorticoid produced and secreted by the cells of the zona
glomerulosa of the adrenal cortex in response to either elevated serum potassium levels or to
angiotensin II (AngII) acting through its type 1 receptors (AT1Rs), endogenously expressed in
the adrenocortical zona glomerulosa (AZG) cells (11). AT1Rs belong to the superfamily of G
protein coupled receptors (GPCRs), and, upon agonist activation, couple to the Gq/11 family of G
proteins (12). Over the past few years, a number of GPCRs, including the AT1Rs, have been
shown to also signal through G protein-independent pathways. The protein scaffolding actions
of β-arrestin-1 and -2 (βarr1 and -2, also known as arrestins -2 and -3, respectively), universal
receptor adapter/scaffolding proteins originally discovered as terminators of GPCR signaling,
play a central role in mediating this G protein-independent signal transduction (13,14).
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We recently reported that adrenal βarr1 promotes AngII-dependent aldosterone
production in vitro in human AZG cells, independently of G-proteins (15). Additionally, adrenalspecific βarr1 overexpression in vivo resulted in a marked elevation of circulating aldosterone
levels in otherwise normal animals (15). In the present study, we sought to investigate whether
adrenal βarr1 plays any role in regulation of circulating aldosterone levels in post-MI HF
progression, as well. For this purpose, we used our previously developed methodology for
adrenal-targeted gene transfer in vivo (16,17), in two-week post-MI rats, of either wild type
βarr1 to induce adrenal βarr1 overexpression or of a βarr1 protein fragment comprising the βarr1
C-terminus, which inhibits βarr1 signaling activity. The two-week post-MI time point was
chosen, since around this time-point circulating aldosterone levels increase dramatically to
accelerate post-MI HF progression in rats (18,19).

4

METHODS
In vivo adrenal gene delivery in post-MI rats. All animal procedures and experiments
were performed in accordance with the guidelines of the IACUC committees of Thomas
Jefferson and Nova Southeastern Universities. MI was performed using a cryo-infarct
method we have previously described (16). Adrenal-specific in vivo gene delivery was
done essentially as described (17), via direct delivery of adenovirus in the adrenal gland.
Drug treatments were performed with 50 mg/kg/day of losartan potassium (in drinking
water) and 100 (or 5) mg/kg/day eplerenone (both drugs from Sigma-Aldrich, USA).

Construction and purification of adenoviruses. Recombinant adenoviruses that encode
full length wild type βarr1 (Adβarr1) or a rat βarr1 C-terminal fragment (aa. 369-418,
Adβarr1ct, see Supplemental Fig. 1A), were constructed as described previously (15,16).
Briefly, transgenes were cloned into shuttle vector pAdTrack-CMV, which harbors a
CMV-driven green fluorescent protein (GFP), to form the viral constructs by using
standard cloning protocols. As control adenovirus, empty vector which expressed only
GFP (AdGFP) was used. The resultant adenoviruses were purified, as described
previously, using two sequential rounds of CsCl density gradient ultracentrifugation
(15,16).

Plasma aldosterone measurements. Rat plasma aldosterone levels were determined by
EIA (Aldosterone EIA kit, ALPCO Diagnostics, Salem, NH, USA), as described (15,20).
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Echocardiographic and hemodynamic measurements. Two-dimensional guided Mmode and Doppler echocardiography using a 14-MHz transducer (Vevo 770 Echograph,
VisualSonic Inc., Toronto, Canada), and closed chest cardiac catheterization were
performed in rats, as described previously (16,21). Three independent echocardiographic
measurements were taken in both modes.

Western blotting. Western blots to assess protein levels of StAR (sc-25806), cardiac
levels of PAI-1 (sc-8979), TGF-β1 (sc-1460), βarr1 transgenes (A1CT antibody, a
generous gift from Dr. R.J. Lefkowitz, Duke University Medical Center, Durham, NC,
USA), and GAPDH (MAB374; Chemicon, Temecula, CA, USA) were done using
protein extracts from rat adrenal glands or hearts, as described previously (15,16).
Visualization of western blot signals was performed with Alexa Fluor 680– (Molecular
Probes) or IRDye 800CW–coupled (Rockland Inc.) secondary antibodies on a LI-COR
infrared imager (Odyssey).

Real-time PCR. Total heart RNA isolation, reverse transcription and real-time RT-PCR
were carried out as previously described (16,21). The following primer pairs were used:
5`-GTCCACGAGGTGACAAAGGT-3` and 5`-CATCTTTTCCAGGAGGTCCA-3` for
Col3α1,

5`-CACCCCTTCTGCGTTGTATT-3`

TTGACCCTAACCAAGGATGC-3`

for

and
Col1α1,

5`5`-

TGCCTGCACCTTTGTGATATCG-3` and 5`-CATGGCAGGACAATCGAACC-3` for
BNP (NPR-B), 5`-CATCCTGGACAACCTGC-3` and 5`-TAGGTCCGAACCTTGCC-3`
for ANP (NPR-A), and, finally, 5′-TCAAGAACGAAAGTCGGAGG-3′ and 5′-
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GGACATCTAAGGGCATCAC-3′ for 18S rRNA. Real time RT-PCR was performed
using SYBR® Green Supermix (Bio-Rad). Normalization was done with 18S rRNA
levels. No bands were seen in the absence of reverse transcriptase.

Masson-Trichrome staining. Masson-trichrome staining was performed as described
(22).

Statistical analyses. Data are generally expressed as mean ± SEM. Unpaired 2-tailed
Student’s t test and one- or two-way ANOVA with Bonferroni test were generally
performed for statistical comparisons, unless otherwise indicated. For most 3-group
statistical comparisons Dunnett’s test using SAS version 8.2 software was used, as well.
For all tests, a p value of <0.05 was generally considered to be significant.

RESULTS
Adrenal βarr1 and post-MI aldosterone levels. In the present study, we set out to
investigate the potential role played by adrenal βarr1 in modulation of in vivo post-MI
HF aldosterone levels. To this end, we overexpressed, specifically in the adrenal glands
of two-week post-MI rats, wild-type βarr1 or a βarr1 C-terminal fragment (βarr1ct),
which is unable to bind receptor substrates, thus acting as an inhibitor of βarr1
scaffolding/signaling activity (Supplemental Fig. 1A). To confirm the inhibitory effects
of βarr1ct on βarr1 activity in vitro, we performed an extensive molecular
characterization of its effects on AngII-induced signaling to aldosterone production in the
human AZG cell line H295R (Supplemental Fig. 1B). βarr1ct was indeed found to
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abrogate βarr1- and G protein-mediated signaling from AT1R to ERK activation and
Steroidogenic Acute Regulatory (StAR) protein up-regulation, both of which signaling
events are absolutely necessary for AngII-driven aldosterone production and secretion
from these adrenocortical cells (15, see Supplemental Fig. 1B). Thus, after confirming
that βarr1ct acts as an inhibitor of adrenal βarr1-mediated aldosterone production in vitro,
we overexpressed either the full length βarr1 (to increase adrenal βarr1 levels/activity) or
the βarr1ct (to inhibit adrenal βarr1 activity in vivo) specifically in the adrenals of the
post-MI rats. Experimental animals were randomized to three different groups: one group
receiving adrenal gene transfer of AdGFP (control group), one receiving full length wild
type βarr1 (Adβarr1), and one receiving the βarr1ct (Adβarr1ct). One day before adrenal
gene transfer, all groups were analyzed by echocardiography to confirm presence of
similar levels of LV dysfunction and HF prior to gene delivery. All groups were then
studied over the course of the following 7 days (i.e. up to 3 weeks post-MI).

In vivo expression of the respective transgenes in the adrenal glands of the
animals at 7 days post-gene delivery was confirmed by Western blotting (Supplemental
Fig. 2). Of note, the adrenal-targeted gene transfer methodology employed results in no
ectopic transgene expression (17 & data not shown). As expected, plasma circulating
aldosterone levels at 7 days post-gene delivery were found markedly elevated in control
AdGFP-treated post-MI rats (470+20 pg/ml, ~2-fold of the aldosterone levels of normal
AdGFP-treated rats) (15), compared to normal (i.e. sham-operated) AdGFP-treated rats,
indicating marked MI-induced aldosterone elevation. Importantly, adrenal βarr1
overexpression resulted in an even more pronounced aldosterone elevation post-MI, on
top of that normally present due to the occurrence of MI (845+150 pg/ml in Adβarr18

treated vs. 470+20 pg/ml in control AdGFP-treated post-MI rats, n=6, p<0.05) (Fig. 1). In
contrast, levels in Adβarr1ct-treated rats (350+30 pg/ml, n=6, p<0.05 vs. AdGFP) were
significantly lower than in control AdGFP-treated post-MI rats (Fig. 1). Aldosterone
levels in post-MI AdGFP rats were similar to saline-treated post-MI rats (data not
shown), indicating no non-specific effects of the adenoviruses used on plasma
aldosterone values.

Consistent with the above findings, βarr1 overexpression led to significant upregulation of adrenal StAR protein, the most critical enzyme in adrenocortical
biosynthesis of aldosterone (as well as of the other adrenal steroids) (15), compared to
control AdGFP-treated post-MI rats, indicating enhanced aldosterone synthesis in vivo,
whereas overexpression of βarr1ct reduced adrenal StAR levels below the levels of the
control rats (Supplemental Fig. 2). Taken together, these results indicate that adrenal
βarr1 promotes post-MI-associated hyperaldosteronism, and inhibition of its activity
reduces aldosterone production and plasma circulating aldosterone levels post-MI in
vivo.

In vivo cardiac function and dimensions at 7 days post-gene delivery. Next, we
examined the impact of this adrenal βarr1-mediated hyperaldosteronism on the post-MI
myocardium. Indeed, we found that ejection fraction (EF) was markedly reduced in
Adβarr1-treated post-MI rats at 7 days post-gene delivery, compared to control AdGFPtreated post-MI rats (41.4+1.2 % vs. 48.7+1.1 %, respectively, n=7, p<0.05) (Fig. 2A).
EF in both groups was similar before gene delivery, and EF of AdGFP-treated rats at 7
days post-gene delivery was slightly but significantly reduced compared to pre-gene
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delivery, as expected, given that cardiac function deteriorates over time after MI,
although at 3 weeks post-MI (when post-gene delivery measurements were taken) there is
limited dysfunction with this model (Fig. 2A). Indeed, previous studies by us have shown
that this model in the rat does not lead to significant cardiac dysfunction before ~10
weeks post-MI (21). Furthermore, LV end diastolic diameter (LVEDD), a marker of
cardiac dimensions, was significantly increased in Adβarr1-treated rats at 3 weeks postMI compared to control AdGFP post-MI rats, in which heart enlargement was less
pronounced at 3 weeks post-MI (Fig. 2B). This indicates that adrenal βarr1
overexpression significantly accelerates the progression of cardiac hypertrophy by
promoting aldosterone elevation post-MI. Of note, EF and LVEDD of saline-treated 3week post-MI rats were similar to those of control AdGFP-treated post-MI rats at 7 days
post-gene delivery, indicating no non-specific effects of the adenoviral gene delivery on
cardiac function (data not shown).
Importantly, these adrenal βarr1-induced cardiac alterations are aldosteronemediated, i.e. due to the elevated aldosterone levels caused by adrenal βarr1
overexpression in vivo, since EF reduction and LVEDD increase are prevented (i.e. are
similar to control AdGFP-treated rats) by treatment of post-MI Adβarr1 rats with the
aldosterone antagonist eplerenone (Figs. 2C&D), although this drug, as expected, has no
effect on the plasma aldosterone increase caused by the Adβarr1 treatment of the adrenals
of these post-MI animals (Supplemental Fig. 3). Of note, eplerenone prevented the effects
of adrenal βarr1 overexpression at two completely different doses (a high one, 100
mg/kg/d, Figs. 2C&D, and a low one, 5 mg/kg/d, data not shown). Thus, the cardiac
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effects observed upon adrenal βarr1 overexpression are indeed mediated by circulating
aldosterone.
Finally, hemodynamic analysis revealed that Adβarr1-treated post-MI rats
exhibited significantly reduced basal and maximal dose of isoproterenol-induced cardiac
contraction and relaxation indices, compared to control AdGFP-treated rats (Figs. 2E&F).
At this early post-MI time-point, when cardiac dysfunction has not yet manifested as HF,
echocardiographic and hemodynamic parameters of Adβarr1ct-treated post-MI rats did
not display statistically significant differences from those of control AdGFP-treated postMI rats, as one might expect, although there was some trend towards functional
improvement in the Adβarr1ct group (see Table 1 for complete in vivo cardiac functional
parameters in all three post-MI groups at one week after gene delivery). These results
show that the adrenal βarr1-mediated hyperaldosteronism indeed results in significantly
accelerated deterioration of function of the post-MI rat heart.

Cardiac remodeling and functional biomarkers at 7 days post-gene delivery. We also
performed molecular and structural evaluation of the post-MI rat hearts at 7 days postgene delivery. Consistent with the in vivo functional data, real time PCR in total mRNA
isolated from these hearts showed a marked upregulation of collagen types 1α1 and 3α1,
markers of cardiac fibrosis, and of ANP (Atrial Natriuretic Peptide) and BNP (B-type
Natriuretic Peptide), markers of cardiac hypertrophy, in the post-MI hearts of Adβarr1treated rats, compared to control AdGFP-treated animals (Figs. 3A-D). Conversely,
upregulation of all these markers was prevented in Adβarr1ct-treated rats (Figs. 3A-D),
despite the fact this group did not show significant improvement in cardiac function,
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which is not surprising given the early post-MI time-point these measurements were
taken at. Thus, lowering of circulating aldosterone levels by adrenal βarr1 inhibition in
vivo causes a marked reduction in the expression of adverse remodeling-related genes,
which might help halt the post-MI cardiac decline at later time-points. Additionally, heart
weight-to-body weight ratio measurements also confirmed the accelerated cardiac
hypertrophy (i.e. enhanced at one week post-adrenal gene delivery, compared to control
AdGFP-treated) displayed by Adβarr1-treated post-MI rats (Table 1, see also above, Fig.
2B).

Cardiac fibrosis at 7 days post-gene delivery. Masson-trichrome staining for cardiac
fibrosis at 3 weeks post-MI (7 days post-gene delivery) showed markedly increased
fibrosis in Adβarr1-adrenal treated rat hearts compared to control AdGFP-treated rat
hearts, whereas fibrosis was almost completely absent in Adβarr1ct-adrenal treated rat
hearts (Figs. 4A&5B). As expected, no fibrosis was detectable in sham-operated rat
hearts (Fig. 4A). In addition, eplerenone treatment markedly reduced fibrosis in Adβarr1adrenal treated rat hearts (Supplemental Fig. 4), thus providing another indication that the
cardiac effects of βarr1 are aldosterone-dependent.

Cardiac mediators of aldosterone at 7 days post-gene delivery. Immunoblotting in
cardiac protein extracts revealed a marked upregulation of cardiac Plasminogen Activator
Inhibitor (PAI)-1 and Transforming Growth Factor-β (TGF-β), two of the most important
molecular mediators of aldosterone`s cardiac fibrotic and adverse remodeling actions (5),
in the post-MI hearts of Adβarr1-treated rats compared to control AdGFP-treated rats
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(Figs. 4C&D).

In contrast, in the hearts of Adβarr1ct-treated rats, not only was

upregulation of PAI-1 and TGF-β prevented, but the levels of these proteins were
actually lowered below the levels of control AdGFP-treated rats (Figs. 4C&D). Taken
together, these results indicate that adrenal βarr1-mediated hyperaldosteronism
accelerates cardiac adverse remodeling and progression to HF after MI, and that these
effects can be reciprocally mitigated by adrenal βarr1 inhibition, which significantly
reduces circulating aldosterone levels.

Angiotensin antagonism and βarr1-mediated aldosterone levels post-MI. Finally, we
examined whether adrenal βarr1 can affect the efficacy of AT1R antagonism at curbing
AngII-induced aldosterone production. For this purpose, we treated post-MI rats with the
prototypic AT1R antagonist losartan (23,24) for the entire 7-day post-gene delivery
period at a dose of 50 mg/kg/day. As expected, in control AdGFP-treated post-MI rats,
losartan produced a small but significant plasma aldosterone reduction (from 470+20 in
saline-treated to 402+10 pg/ml in losartan-treated rats, p<0.05, n=6) (Fig. 5).

In

Adβarr1-treated post-MI rats however, losartan is virtually unable to lower aldosterone
levels (845+150 in saline-treated vs. 880+88 pg/ml in losartan-treated rats, Not
Significant at p<0.05, n=6) (Fig. 5). In the Adβarr1ct-treated group, no significant
aldosterone reduction by losartan was observed, probably because plasma aldosterone
levels were already reduced below the levels of AdGFP-treated rats by Adβarr1ct alone.
Consistent with this, losartan seems also incapable of reducing the cardiac fibrosis
induced by adrenal βarr1-mediated hyperaldosteronism (Supplemental Fig. 4). However,
levels in both the saline- and losartan-treated Adβarr1ct rats were significantly lower than
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in vehicle-administered control AdGFP post-MI rats (Fig. 5). These results strongly
suggest that losartan`s post-MI aldosterone lowering effects are antagonized by adrenal
βarr1, therefore, adrenal βarr1 inhibition can potentiate the hypoaldosteronic actions of
this drug in post-MI HF. Effects of losartan in AdGFP-treated and saline-treated post-MI
rats were similar (data not shown).

DISCUSSION
We recently reported that adrenal βarr1 promotes AngII-dependent aldosterone
production in vitro in human AZG cells, independently of G-proteins (15). Additionally,
adrenal-specific βarr1 overexpression in vivo resulted in marked elevation of circulating
aldosterone levels in otherwise normal animals (15). In the present study, we sought to
investigate whether adrenal βarr1 plays any role in regulation of circulating aldosterone
levels in post-MI HF progression. We found that adrenal βarr1 is indeed a crucial
regulator of circulating aldosterone levels in vivo during post-MI HF progression, in that
increased adrenal βarr1 levels/activity promotes aldosterone elevation post-MI, resulting
in accelerated cardiac adverse remodeling and deterioration of function, whereas
blockade of its activity in vivo lowers post-MI aldosterone levels, attenuating or even
preventing these detrimental effects of aldosterone on the failing heart.
These findings strongly suggest that blockade of adrenal βarr1 action on AT1R
might serve as a novel therapeutic strategy for lowering aldosterone levels post-MI and in
HF. This is particularly important, since aldosterone has been shown to exert some of its
actions (its so-called “non-genomic” actions) independently of the mineralocorticoid
receptor (MR), its molecular target that normally mediates its cellular actions (4,5). These
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MR-independent actions are unaffected by the currently available MR antagonists, such
as eplerenone and spironolactone, used in the treatment of HF (9,10). Therefore, curbing
aldosterone production at its major source, i.e. the adrenal cortex, by inhibiting βarr1
actions, could presumably be more effective therapeutically than inhibiting aldosterone`s
actions at its receptor level.
In addition, since adrenal βarr1 appears necessary for upregulation of StAR, the
enzyme that regulates synthesis of all adrenal steroids, its inhibition presumably leads to
suppression of the production of the other adrenocortical steroids as well, i.e. of
glucocorticoids and corticosterone (15). Of note, glucocorticoids have been reported to
actually occupy the cardiac mineralocorticoid receptors under normal conditions instead
of aldosterone (25). Therefore, adrenal βarr1 inhibition, by suppressing production of
glucocorticoids and mineralocorticoids alike, has the unique potential of keeping cardiac
MRs completely at bay. For this very same reason, adrenal βarr1 emerges as a much
superior target for post-MI cardiac remodeling and heart failure treatment than MR
inhibition (e.g. with eplerenone) or aldosterone synthase inhibition, given that the latter
strategies cannot counter all the adverse effects of all adrenal steroids post-MI, as
suppression of all adrenal steroid production via adrenal βarr1 inhibition is projected to
do.
Another important ramification of the present study is that pathological situations
that cause elevation of adrenal βarr1 activity towards receptors can lead to abnormally
high AngII-induced aldosterone production and hyperaldosteronism. Indeed, we recently
reported that in chronic HF, adrenal GRK2, a protein kinase that induces receptor-βarr
coupling, is dramatically upregulated resulting in chronically enhanced catecholamine
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production by the adrenal medulla (16). Thus, it is entirely plausible that, driven by the
enhanced GRK2 activity, adrenal βarr1 activity towards receptors, including the AT1Rs,
is also increased in chronic HF or during progression from MI to HF, which could
mediate (at least in part) the chronically elevated circulating levels of aldosterone that
precipitate this disease. Importantly, we have previously shown that GRK2 can
desensitize AngII receptors in the heart in vivo (26), and that overexpression of GRK2 in
rat adrenal glands also causes elevation of plasma aldosterone (15). Both of these
findings argue in favor of the aforementioned scenario.
Furthermore, it is now well established that, in addition to the circulatory reninangiotensin-aldosterone system (RAAS), there are also several other local RAAS`s in
peripheral tissues, including the heart (intracardiac RAAS) and the kidneys (intrarenal
RAAS), and these systems also hyperfunction in HF contributing to the HF-associated
hyperaldosteronism (27,28). Therefore, it would be worth investigating whether βarr1 is
involved in aldosterone production by these local RAAS`s, and whether it contributes to
their increased aldosterone output during HF as well.

In fact, specifically for the

intracardiac RAAS, this possibility is very likely, given the elevated cardiac GRK2 levels
in HF (29).
One of the major physiological effects of aldosterone is an increase in blood
pressure via salt and water retention (4,5). Thus, alterations in mean arterial pressure by
the elevated aldosterone levels caused by adrenal βarr1 overactivity might very well have
contributed to the observed cardiac phenotype of adrenal βarr1-overexpressing post-MI
rats. It should be noted here however that βarr1 knockout mice do not show any changes
in blood pressure compared to wild type age-matched control mice (30). Additionally, the
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direct effects of aldosterone on cardiac tissue are bound to have played the most
important role in the observed cardiac phenotype of the post-MI animals, given the
relatively small time-period (only 7 days) between genetic manipulation of adrenal βarr1
levels which raises aldosterone levels (i.e. gene delivery) and the day of cardiac
measurements/examination, which is rather insufficient for blood pressure to affect
cardiac function and remodeling that dramatically. Besides, whether changes in blood
pressure play any role in the cardiac effects of aldosterone is still an open question in its
own right, since there are several reports in the literature showing aldosterone to affect
cardiac function and fibrosis in post-MI rats independently of changes in mean blood
pressure (31,32). Indeed, no differences in systemic mean arterial pressure among the
three post-MI treatment groups of the present study (i.e. AdGFP, Adβarr1, Adβarr1ct)
were observed at one week post-gene delivery (data not shown), further supporting the
notion that blood pressure did not play any major role in the observed cardiac effects of
βarr1-dependent aldosterone at this early post-MI time-point (3 weeks).
The last finding of the present study is that the aldosterone-lowering actions of
losartan, the prototypic drug of the class of AT1AR antagonists (sartans) (23,24), are
countered by adrenal βarr1. Although at normal βarr1 levels (control AdGFP-treated
post-MI rats) it is capable of producing a small but significant plasma aldosterone
lowering as expected, when adrenal βarr1 is overactive (Adβarr1-treated post-MI rats),
losartan does not decrease plasma aldosterone at all. This finding implies that inhibition
of adrenal βarr1 in vivo can facilitate the inhibitory effects of losartan (and possibly also
of the other sartans) on AngII-induced aldosterone production. Of note, limited efficacy
of losartan and other sartans at lowering aldosterone levels in HF patients and in
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experimental animals, the so-called “aldosterone escape”, has been reported (20,33,34).
Therefore, the finding that losartan`s effects on aldosterone production can be
antagonized by adrenal βarr1-AT1R coupling might explain (at least in part) this reported
limited efficacy of losartan and related drugs at curbing aldosterone levels. On the other
hand, increased activity of the βarr1 co-factor GRK2 on cardiac AT1Rs also attenuates
the pro-contractile signaling of these receptors (26). Therefore, the development of novel,
functionally selective (or “biased”) AT1R ligands (35,36), which would inhibit AT1Rinduced GRK2/βarr1 activation, at least as effectively as AT1R-induced G-protein
activation, might prove extremely beneficial in the treatment of HF-related
hyperaldosteronism and decreased cardiac function.
Clinical implications. We have found that circulating aldosterone levels are
reciprocally regulated by adrenal βarr1 activity in vivo, in that they are directly
proportional to βarr1 activity toward AngII receptors in the adrenal glands. Therefore,
inhibiting adrenal βarr1 action markedly decreases circulating aldosterone and attenuates
its detrimental effects on the post-MI heart, such as fibrosis, hypertrophy, and dilatation,
thereby preventing or even reversing adverse remodeling post-MI and maintaining
cardiac function in the face of post-MI-driven cardiac decline. Additionally, losartan, a
classical AngII receptor antagonist drug used in the treatment of hypertension, appears
unable to counter this adrenal βarr1-promoted hyperaldosteronism post-MI. Taken
together, the present findings suggest adrenal βarr1 as a major driving force behind postMI aldosterone elevation, whose inhibition in vivo, either via gene therapy or
pharmacologically, could potentially be of enormous therapeutic value in the
management of post-MI HF patients. Finally, from the pharmacotherapeutic standpoint,
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an evaluation of the whole class of AT1R antagonists (sartans) in terms of their efficacy
at antagonizing βarr1-driven hyperaldosteronism is highly warranted, as it could help
explain some well-known existing differences in therapeutic efficacy, and also identify
the most efficacious agents at lowering post-MI aldosterone, within this very important
cardiovascular drug class.
In summary, the present study reports that adrenal βarr1 promotes the welldocumented post-MI-associated elevation of circulating aldosterone, and thus, direct
inhibition of its activity via adrenal-targeted gene therapy or via development of novel
AT1R “biased” or “functionally selective” ligands that can prevent/reduce GRK2/βarr1
activation by the AT1R might be of therapeutic value in post-MI ensuing HF, as well as
in already established chronic HF, both of which are precipitated by the cardiotoxic
actions of elevated aldosterone.
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FIGURE LEGENDS

Figure 1. Regulation of plasma aldosterone levels by adrenal βarr1. Plasma aldosterone
levels in AdGFP-, Adβarr1-, or Adβarr1ct-treated two-week post-MI rats, at 7 days postin vivo gene delivery. *, p<0.05, vs. AdGFP, **, p<0.05 vs. Adβarr1, n=6 rats/group.

Figure 2. Effect of adrenal βarr1-mediated hyperaldosteronism on cardiac function,
dimensions and contractility. (A) Ejection fraction (EF%) of Adβarr1- and control
AdGFP-treated post-MI rats pre- and post-gene delivery (see also Table 1). *, p<0.05, vs.
AdGFP-post-gene delivery or Adβarr1-pre-gene delivery, **, p<0.05, vs. AdGFP-pregene delivery, n=7 rats/group. (B) Left Ventricular End Diastolic Diameter (LVEDD) of
these rats. *, p<0.05, vs. AdGFP-post-gene delivery or Adβarr1-pre-gene delivery, n=7
rats/group. (C) Ejection fraction (EF%) and (D) Left Ventricular End Diastolic Diameter
(LVEDD) of Adβarr1-treated post-MI rats administered either with saline (vehicle) or
with eplerenone (Adβarr1-Eplerenone) for 7 days, at 1 week post-gene delivery (3 weeks
post-MI). AdGFP post-MI rats (treated with vehicle) are also shown at 1 week post-gene
delivery (3 weeks post-MI) for comparisons. *, p<0.05, vs. either AdGFP or Adβarr1Eplerenone, no significant difference between AdGFP and Adβarr1-Eplerenone was
observed at p=0.05, n=5 rats/group. (E, F) Basal and maximal dose of isoproterenol
(Max. Iso)-stimulated +dP/dtmax (E) and –dP/dtmin (F) responses of Adβarr1- and control
AdGFP-treated post-MI rats at 7 days post-adrenal gene delivery (see also Table 1). *,
p<0.05, vs. AdGFP, n=7 rats/group.

24

Figure 3. Effect of aldosterone levels on cardiac remodeling markers. Heart mRNA
levels of (A) collagen I (Col1a1); (B) collagen III (Col3a1); (C) atrial natriuretic peptide
(ANP); (D) brain natriuretic peptide (BNP) in all experimental groups at 7 days post-gene
delivery (3 weeks post-MI). All values were standardized to amplified 18S rRNA. Data
are presented as mean ± SEM and plotted as fold of AdGFP values. *, p<0.05, vs.
AdGFP or Adβarr1ct, **, p<0.05 vs. AdGFP, n=5 rat hearts/group.

Figure 4. Impact of aldosterone levels on cardiac fibrosis and adverse remodeling
mediators. (A) Trichrome-Masson`s staining in myocardial cross-sections from AdGFP-,
Adβarr1-, or Adβarr1ct-treated post-MI rats at 7 days post-adrenal gene delivery. Blue
denotes collagen fibers, red denotes muscle fibers, and black represents cell nuclei.
Representative images are shown from 5-6 rat hearts stained per group, along with
staining in sham rat hearts, in which no blue staining was detectable. (B) Quantification
of the % fibrotic area visualized upon Trichrome-Masson`s staining. *, p<0.05, vs.
AdGFP, **, p<0.05 vs. Adβarr1, n=5-6 rat hearts/group. (C) Western blotting for cardiac
PAI-1 and TGF-β1 in AdGFP-, Adβarr1-, or Adβarr1ct-treated post-MI rats, at 7 days
post-gene delivery, including GAPDH as loading control. (D) Densitometric analysis of 5
heart samples tested per group. *, p<0.05, vs. AdGFP, **, p<0.05 vs. Adβarr1, n=5 rat
hearts/group.

Figure 5. Adrenal βarr1-dependent aldosterone levels and losartan. Plasma aldosterone
levels 7 days post-adrenal gene delivery of post-MI rats after concomitant vehicle (-Los)
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or losartan (+Los) treatment. *, p<0.05, vs. AdGFP/-Los or Adβarr1/+Los, n=5
rats/group/treatment.
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